Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

OBJECTIVES: Interventions aimed at increasing TNF-α inhibitor serum drug levels (SDLs) may improve treatment response; however, previous studies suggesting SDL cut-offs have not accounted for treatment adherence. The aim of this study was to establish the relationship between adalimumab/certolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Hum, Ryan M, Ho, Pauline, Nair, Nisha, Jani, Meghna, Morgan, Ann W, Isaacs, John D, Wilson, Anthony G, Hyrich, Kimme L, Plant, Darren, Barton, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234202/
https://www.ncbi.nlm.nih.gov/pubmed/36190343
http://dx.doi.org/10.1093/rheumatology/keac564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234202/
https://www.ncbi.nlm.nih.gov/pubmed/36190343
http://dx.doi.org/10.1093/rheumatology/keac564

Ejemplares similares